## Arpad Szallasi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1070271/publications.pdf Version: 2024-02-01



Δραλη ζζλιιλςι

#	Article	lF	CITATIONS
1	Capsaicin and cancer: Guilty as charged or innocent until proven guilty?. Temperature, 2023, 10, 35-49.	3.0	5
2	Advances in TRP channel drug discovery: from target validation to clinical studies. Nature Reviews Drug Discovery, 2022, 21, 41-59.	46.4	206
3	Functional Transient Receptor Potential Ankyrin 1 and Vanilloid 1 Ion Channels Are Overexpressed in Human Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 1921.	4.1	12
4	Desensitization of Capsaicin-Sensitive Afferents Accelerates Early Tumor Growth via Increased Vascular Leakage in a Murine Model of Triple Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 685297.	2.8	10
5	Transient Receptor Potential (TRP) Channels in Head-and-Neck Squamous Cell Carcinomas: Diagnostic, Prognostic, and Therapeutic Potentials. International Journal of Molecular Sciences, 2020, 21, 6374.	4.1	18
6	The Mysteries of Capsaicin-Sensitive Afferents. Frontiers in Physiology, 2020, 11, 554195.	2.8	29
7	TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation?. Medical Sciences (Basel, Switzerland), 2019, 7, 82.	2.9	11
8	Reversal of warfarin-coagulopathy: How to improve plasma transfusion practice in a community hospital setting?. Asian Journal of Transfusion Science, 2019, 13, 100.	0.3	0
9	Targeting nociceptive <b>transient receptor potential</b> channels to treat chronic pain: current state of the field. British Journal of Pharmacology, 2018, 175, 2185-2203.	5.4	154
10	Manipulating transient receptor potential vanilloid 1 antagonists: How to cool down a hot molecule?. Acta Physiologica, 2018, 223, e13088.	3.8	1
11	Improving Blood Transfusion Practices in a Community Hospital Setting: Our Experience with Real-Time Clinical Decision Support. Medical Sciences (Basel, Switzerland), 2018, 6, 67.	2.9	3
12	TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?. Trends in Molecular Medicine, 2017, 23, 1002-1013.	6.7	36
13	Terminal Deoxynucleotidyl Transferase (TdT)-negative Lymphoblastic Leukemia in Pediatric Patients: Incidence and Clinical Significance. Pediatric and Developmental Pathology, 2017, 20, 463-468.	1.0	11
14	Transient Receptor Potential (TRP) Channels in Drug Discovery: Old Concepts & New Thoughts. Pharmaceuticals, 2017, 10, 64.	3.8	11
15	Thrombocytosis Portends Adverse Prognosis in Colorectal Cancer: A Meta-Analysis of 5,619 Patients in 16 Individual Studies. Anticancer Research, 2017, 37, 4717-4726.	1.1	21
16	Some like it hot (ever more so in the tropics): A puzzle with no solution. Temperature, 2016, 3, 54-55.	3.0	7
17	Transient receptor potential ankyrin 1 (TRPA1) antagonists. Pharmaceutical Patent Analyst, 2015, 4, 75-94.	1.1	42
18	Feeling hot, feeling cold: TRP channels—a great story unfolds. Temperature, 2015, 2, 150-151.	3.0	6

ARPAD SZALLASI

#	Article	IF	CITATIONS
19	Transient Receptor Potential Channels and Itch: How Deep Should We Scratch?. Handbook of Experimental Pharmacology, 2015, 226, 89-133.	1.8	23
20	Prevention of surgical delays by pre-admission type and screen in patients with scheduled surgical procedures: improved efficiency. Blood Transfusion, 2015, 13, 310-2.	0.4	1
21	Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine. Pharmacological Reviews, 2014, 66, 676-814.	16.0	440
22	Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma. F1000Research, 2014, 3, 180.	1.6	14
23	Case Report: Primary Leiomyosarcoma of the breast with unusual metastasis to the femur. F1000Research, 2014, 3, 211.	1.6	0
24	"Transfusion indication RBC (PBM-02)": gap analysis of a Joint Commission Patient Blood Management Performance Measure at a community hospital. Blood Transfusion, 2014, 12 Suppl 1, s187-90.	0.4	13
25	Targeting TRPV1 for pain relief: limits, losers and laurels. Expert Opinion on Investigational Drugs, 2012, 21, 1351-1369.	4.1	122
26	Transient receptor potential channels as therapeutic targets. Nature Reviews Drug Discovery, 2011, 10, 601-620.	46.4	472
27	Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials. Current Topics in Medicinal Chemistry, 2011, 11, 2159-2170.	2.1	85
28	Human Correlates of Animal Models of Chronic Pain. Methods in Molecular Biology, 2010, 617, 155-157.	0.9	1
29	NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Current Opinion in Investigational Drugs, 2009, 10, 702-10.	2.3	51
30	Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists. Expert Opinion on Therapeutic Patents, 2008, 18, 159-209.	5.0	34
31	Medicinal chemistry of the vanilloid (Capsaicin) TRPV1 receptor: current knowledge and future perspectives. Drug Development Research, 2007, 68, 477-497.	2.9	32
32	The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nature Reviews Drug Discovery, 2007, 6, 357-372.	46.4	754
33	TRPV1: a therapeutic target for novel analgesic drugs?. Trends in Molecular Medicine, 2006, 12, 545-554.	6.7	154
34	Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 273-286.	3.0	33
35	4 Clinically Useful Vanilloid Receptor TRPV1 Antagonists: Just around the Corner (or too Early to) Tj ETQq1 1 0.7	784314 rgBT 10.4	[ /Overlock ]
36	Piperine: researchers discover new flavor in an ancient spice. Trends in Pharmacological Sciences,	8.7	58

2005, 26, 437-9.

ARPAD SZALLASI

#	Article	IF	CITATIONS
37	Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3655-3660.	7.1	706
38	Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3655-3660.	7.1	388
39	Vanilloid (Capsaicin) receptors and mechanisms. Pharmacological Reviews, 1999, 51, 159-212.	16.0	1,412
40	The stimulation of capsaicinâ€sensitive neurones in a vanilloid receptorâ€mediated fashion by pungent terpenoids possessing an unsaturated 1,4â€dialdehyde moiety. British Journal of Pharmacology, 1996, 119, 283-290.	5.4	54
41	Capsaicinâ€; Resiniferatoxinâ€; and Lactic Acidâ€Evoked Vascular Effects in the Pig Nasal Mucosa <i>in vivo</i> with Reference to Characterization of the Vanilloid Receptor. Basic and Clinical Pharmacology and Toxicology, 1996, 78, 327-335.	0.0	10
42	Vanilloid-sensitive neurons: a fundamental subdivision of the peripheral nervous system. Journal of the Peripheral Nervous System, 1996, 1, 6-18.	3.1	9
43	Resiniferatoxin binding to vanilloid receptors in guinea pig and human airways American Journal of Respiratory and Critical Care Medicine, 1995, 152, 59-63.	5.6	94
44	Autoradiographic visualization and pharmacological characterization of vanilloid (capsaicin) receptors in several species, including man. Acta Physiologica Scandinavica Supplementum, 1995, 629, 1-68.	1.0	30
45	Vanilloid receptor loss in rat sensory ganglia associated with long term desensitization to resiniferatoxin. Neuroscience Letters, 1992, 140, 51-54.	2.1	66
46	Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience, 1989, 30, 515-520.	2.3	403
47	Role of TRP Channels in Pain: An Overview. , 0, , 68-100.		0
48	Vanilloid (TRPV1) and Other Transient Receptor Potential Channels. , 0, , 175-213.		1